Synthesis of a novel 99mtechnetium fatty acid
✍ Scribed by G.S. Jones; D.R. Elmaleh
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- French
- Weight
- 89 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0022-2135
No coin nor oath required. For personal study only.
✦ Synopsis
A s p a r t of o u r program t o develop u s e f u l r a d i o i m a g i n g a g e n t s f o r t h e myocardium, chose t o i n v e s t i g a t e t h e f e a s i b i l i t y of i n c o r p o r a t i n g an e f ficacious.w'%c-complexing, d i a m i n o d i t h i o l l i g a n d i n t o a l o n g c h a i n f a t t y a c i d . A similar approach h a s been pursued o n l y once b e f o r e (1). t o o u r knowledge. The r e s u l t s of t h a t s t u d y , r e p o r t e d i n a b s t r a c t form, were i n c o n c l u s i v e , p a r t i c u l a r l y i n r e g a r d t o t h e c h a r a c t e r i z a t i o n of t h e complex.
📜 SIMILAR VOLUMES
The hitherto unknown (±)-4-methoxydecanoic acid was synthesized in six steps and in 25% overall yield starting from commercially available 4-penten-1-ol. The title compound demonstrated seventeen fold higher antifungal activity (MIC = 1.5 mM) against Candida albicans ATCC 60193 and Cryptococcus. neo
## Abstract ^123^I‐iodophenylpentadecanoic acid (IPPA) and ^123^I‐beta‐methyliodophenylpentadecanoic acid (BMIPP) are radiolabelled fatty acid derivatives used for assessment of myocardial viability. Because of limited accessibility of ^123^I in the clinical scenario, a 99m‐technetium‐based agent w